CSE CALI  |  Last $0.12  |  Change 0.00 OTC FNNZF  |  Last $0.10  |  Change 0.00
  • Refined Resin Technologies is a cannabinoid research and refinery company that provides B2B and B2C products and services to licensed dispensaries and distributors in the medical cannabis supply chain;

  • Refined Resin has a facility in Oakland, California under a long-term lease, which it will retrofit a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating by early 2019;

  • Refined Resin also plans to provide white-labeling services to licensed brands and infused product manufacturers who do not have direct access to compliant production facilities;

  • Refined Resin’s principles have extensive experience in extraction, manufacturing and business operations, and will also be bringing over their existing brand from their registered collective “California Extracts”. California Extracts already has an existing industry following and market presence;

  • Under the Royalty Agreement, FinCanna will fund US$3.5 million cash in tranches and US$1.295 million in shares of FinCanna to earn a perpetual royalty ranging from 16% to 7.0% of Refined Resin’s consolidated annual revenues, based on agreed upon benchmarks and subject to certain buy-back options;

  • The effective royalty rate to FinCanna is 11.75% on the first US$160 million of Refined Resin’s consolidated annual revenues

For additional details on the Refined Resin royalty agreement, please see press releases dated February 15, 2018 and July 10, 2018

Subscribe for Updates